ArticleNature communications2026
Trdn-as directs m6A-dependent transcriptional termination for accurate triadin isoform switching, preventing aberrant dyads and cardiomyopathy.
Theresa Hofmann, Sara Hettrich, Bio Maria Ghéo Idrissou, Christian Waechter, Maria Weiss, Salma Hachim, Silke Kreher, Maximilian Staps, Laia Cañes Esteve, Sabine Pankuweit and 6 more
Abstract read
In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Theresa HofmannDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.
Sara HettrichDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0009-0006-8355-3349 Bio Maria Ghéo IdrissouInstitute of Pharmacology and Toxicology, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0002-4650-2511 Christian WaechterDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0000-0003-1558-0696 Maria WeissDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.
Salma HachimDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.
Silke KreherDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0009-0001-0890-2979 Maximilian StapsDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0009-0006-7294-4563 Laia Cañes EsteveDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID 0000-0002-9579-1321 Sabine PankuweitDepartment of Cardiology, Philipps University Marburg, Marburg, Germany.
Hendrik MiltingHeart- and Diabetescenter NRW, Klessmann-Institute for Cardiovascular Research and Development, Ruhr-University Bochum, Bad Oeynhausen, Germany.
Mario LoosoMember of the German Centre for Cardiovascular Research (DZHK), Partner site Rhein-Main, Frankfurt am Main, Germany.ORCID 0000-0003-1495-9530 Isabelle MartyGrenoble Institut Neurosciences, University Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble, France.ORCID 0000-0003-3625-913X Stefan EngelhardtInstitute of Pharmacology and Toxicology, School of Medicine, Technical University of Munich, Munich, Germany.ORCID 0000-0001-5378-8661 Thomas BraunDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany. thomas.braun@mpi-bn.mpg.de.ORCID 0000-0002-6165-4804 Thomas BoettgerDepartment of Cardiac Development and Remodelling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany. thomas.boettger@mpi-bn.mpg.de.ORCID 0000-0003-4280-8449 Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) TRR267Deutsche Forschungsgemeinschaft (German Research Foundation) TRR267, RTG2355
6 · The paper itselfAbstract
Heart failure is a leading cause of mortality, and impaired cardiac excitation-contraction coupling represents a potentially fatal trigger for myocardial dysfunction. Long non-coding RNAs (lncRNAs) can contribute to cardiomyopathy, but comprehensive mechanistic insights remain elusive. We demonstrate that reduction of the lncRNA TRDN-AS in human cardiomyopathy or abrogating it in human iPSC-derived cardiomyocytes and mice causes a switch of cardiac TRDN/TRISK32 to skeletal muscle TRDN/TRISK95. Transcription of Trdn-as in cis is essential for stalling RNA Pol II at the 3' end of the cardiac Trdn transcript, promoting the formation of the cardiac TRDN/TRISK32 isoform. The m6A-methyltransferase METTL3 is crucial for RNA Pol II stalling, enforcing transcriptional termination and proximal polyadenylation of the Trdn transcript. Here, we establish that the switch of TRDN isoforms results in a significantly altered interactome of the cardiac calcium release complex, aberrant calcium handling, altered dyad structure, QT prolongation, and dilated cardiomyopathy in mice and humans.
Indexed as
CardiomyopathiesCarrier ProteinsMuscle ProteinsRNA, Long NoncodingTranscription Termination, GeneticAnimalsCalciumEpitranscriptomeHumansInduced Pluripotent Stem CellsMaleMethyltransferasesMiceMuscle, SkeletalMyocytes, CardiacProtein IsoformsCalciumCarrier ProteinsMethyltransferasesMettl3 protein, mouseMuscle ProteinsProtein IsoformsRNA, Long NoncodingRNA Polymerase IIUbiquitin-Protein Ligases
Identifiers
PMID42502078
PMCPMC13401598
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390